Lpath is the leader in the discovery and development of monoclonal antibodies targeted to bioactive lipids for the treatment of important human diseases that currently lack innovative and effective medicines. Lpath’s unique ability to generate antibodies against bioactive lipids is based on its proprietary ImmuneY2 drug-discovery engine. The company is currently applying the ImmuneY technology to other important bioactive lipid targets, many of which are involved in important disease processes such as inflammation, cancer, pain, asthma, sepsis, and others, adding to the company’s pipeline of novel antibody-based drug candidates.
Lpath’s proprietary ImmuneY drug-discovery engine generates monclonal antibodies against bioactive-lipid targets, a novel approach that has distinct potential advantages over standard protein targeting approaches when it comes to fighting cancer and other diseases. Bioactive lipids are much smaller and simpler molecules than proteins, and generally do not vary from species to species. When the target in humans is exactly the same as in mice (and in monkeys), compelling mouse (and monkey) data are more predictive of success in the clinical setting. In addition, cancer cells (and other pathogenic cell types) can much more easily escape therapy by mutating around protein-targeted drugs versus lipid-targeted drugs, and antibodies that bind to lipids can also attain certain efficiencies and potencies that protein-targeted antibodies cannot.
Lpath’s founder, Roger Sabbadini, Ph.D., helped pioneer the bioactive lipid signaling space. As such, the company has deep and broad knowledge of lipids and how to work with them. They have demonstrated a unique ability to generate monoclonal antibodies against bioactive lipids, setting them apart from the rest of the field. Lpath’s lead product candidate, iSONEP, is currently in two clinical trials. Lpath’s second product candidate, ASONEP, has completed a phase I clinical trial in cancer patients. Lpath’s third product candidate, Lpathomab is a monoclonal antibody against a key bioactive lipid recognized to be involved in diseases of the central nervous system, fibrosis, ocular disease, and cancer, and has demonstrated strong preclinical activity in several animal models of these diseases.
Lpath currently has over 100 issued or pending patents in the U.S. (with corresponding patent protection in Europe, Japan, etc.). Most of these patents were developed in-house using the company’s proprietary technologies and expertise. Several patents issued and pending provide broad coverage of bioactive lipids as targets in the treatment of several diseases, including cancer, cardiovascular diseases, inflammation, autoimmune disorders, ocular disease, and pathogenic angiogenesis. As a result of Lpath’s pioneering work in the field, many of these issued and allowed patents may be considered dominating.
For additional information, visit the company’s website at www.Lpath.com
Let us hear your thoughts below:
